GALECTIN THERAPEUTICS INC 8-K

What Happened
Galectin Therapeutics Inc. announced on June 23, 2026 that it issued a press release reporting the results of a recent Type C meeting with the U.S. Food and Drug Administration (FDA). The company furnished the press release as Exhibit 99.1 to a Form 8-K under Item 7.01 (Regulation FD Disclosure).

Key Details

• Filing date: June 23, 2026 (Form 8-K filed with the SEC).
• Event: Results from a Type C meeting with the U.S. FDA were disclosed via press release.
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8-K.
• Item reported: Item 7.01 (Regulation FD Disclosure); Exhibit list included under Item 9.01.

Why It Matters
FDA Type C meetings typically cover clinical development plans, regulatory feedback, and next steps for drug development programs. The company’s press release contains the specifics of the FDA discussion and any regulatory guidance that could affect Galectin’s clinical timeline or strategy. Investors should read the Exhibit 99.1 press release for the detailed outcomes and any implications for the company’s programs.